Myriad Genetics vs Neogen
MYGN and NEOG side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MYGN and NEOG compare
Neogen is the larger company, worth 4.5 times as much as Myriad Genetics ($2.4B against $533M).
Neogen grew revenue faster over the last twelve months (−0.33% versus −3.2% for Myriad Genetics).
Neogen keeps more of each dollar of sales as profit, with a net margin of −6.3% compared with −14.0% at Myriad Genetics.
Neogen scores higher on the StockData Score (7 against 6 for Myriad Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MYGN | NEOG |
|---|---|---|
| Size and price | ||
| Market cap | $533M | $2.4B |
| Share price | $5.57 | $10.88 |
| Change, 1 year | −12.3% | 70.8% |
| Change, 5 years | −79.1% | −73.6% |
| Beta (5Y) | −0.10 | 0.86 |
| Employees | 2,700 | 2,636 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 2 (better) |
| Performance score | 3 | 3 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.7× (better) | 2.7× |
| P/B | 1.8× | 1.1× (better) |
| EV/EBITDA | – | 34.5× |
| P/FCF | – | 47.7× |
| FCF yield | – | 2.1% |
| Fair value | – | $7.30 |
| Margin of safety | – | −49.0% |
| Growth | ||
| Revenue growth (TTM) | −3.2% | −0.33% (better) |
| Revenue growth, 5Y average | −0.63% | 13.2% (better) |
| Profitability | ||
| Gross margin | 68.8% (better) | 47.4% |
| Operating margin | −12.2% | −0.83% (better) |
| Net margin | −14.0% | −6.3% (better) |
| FCF margin | – | 5.6% |
| Return on equity | −32.5% | −2.7% (better) |
| Return on invested capital | −22.8% | −0.17% (better) |
| Financial health | ||
| Debt / equity | 0.40 (better) | 0.74 |
| Net debt / EBITDA | – | 12.69 |
| Interest coverage | −6.0× | – |
| Current ratio | 2.21 | 3.90 (better) |
| Altman Z-score | −0.62 | 1.35 (better) |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 94.1% | 109% |
| Held by insiders | 7.2% | 0.60% |
| Insider net buying, 12 months | $655K (better) | −$102K |
| Short interest, % of float | 9.5% | 5.9% |
Go deeper
- MYGN stock overview
- MYGN income statement
- MYGN valuation and score
- NEOG stock overview
- NEOG income statement
- NEOG valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.